BeiGene Provides Update on the Ociperlimab (BGB-A1217) Clinical Development Program
Beigene, Ltd. (NASDAQ: ONC) was given a new $259.00 price target on by analysts at Sanford C. Bernstein.
Beigene, Ltd. (NASDAQ: ONC) had its "buy" rating re-affirmed by analysts at Guggenheim.
Beigene, Ltd. (NASDAQ: ONC) was given a new $348.00 price target on by analysts at JMP Securities.
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy [Yahoo! Finance]